{"version":"6.9","hitCount":1,"request":{"queryString":"EXT_ID:34170647","resultType":"core","cursorMark":"*","pageSize":25,"sort":"","synonym":false},"resultList":{"result":[{"id":"34170647","source":"MED","pmid":"34170647","doi":"10.1056/nejmoa2107519","title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.","authorString":"Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K, SURPASS-2 Investigators.","authorList":{"author":[{"fullName":"Frías JP","lastName":"Frías","firstName":"Juan P","initials":"JP","authorId":{"type":"ORCID","value":"0000-0001-9486-1255"},"authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre - both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.)."}]}},{"fullName":"Davies MJ","lastName":"Davies","firstName":"Melanie J","initials":"MJ","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre - both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.)."}]}},{"fullName":"Rosenstock J","lastName":"Rosenstock","firstName":"Julio","initials":"J","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre - both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.)."}]}},{"fullName":"Pérez Manghi FC","lastName":"Pérez Manghi","firstName":"Federico C","initials":"FC","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre - both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.)."}]}},{"fullName":"Fernández Landó L","lastName":"Fernández Landó","firstName":"Laura","initials":"L","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre - both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.)."}]}},{"fullName":"Bergman BK","lastName":"Bergman","firstName":"Brandon K","initials":"BK","authorId":{"type":"ORCID","value":"0009-0006-3668-7686"},"authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre - both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.)."}]}},{"fullName":"Liu B","lastName":"Liu","firstName":"Bing","initials":"B","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre - both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.)."}]}},{"fullName":"Cui X","lastName":"Cui","firstName":"Xuewei","initials":"X","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre - both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.)."}]}},{"fullName":"Brown K","lastName":"Brown","firstName":"Katelyn","initials":"K","authorAffiliationDetailsList":{"authorAffiliation":[{"affiliation":"From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre - both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.)."}]}},{"collectiveName":"SURPASS-2 Investigators"}]},"investigatorList":{"investigator":[{"fullName":"Rosenstock J","lastName":"Rosenstock","firstName":"Julio","initials":"J"},{"fullName":"Welch M","lastName":"Welch","firstName":"Michelle","initials":"M"},{"fullName":"Connery L","lastName":"Connery","firstName":"Lisa","initials":"L"},{"fullName":"Gardner DF","lastName":"Gardner","firstName":"Donald F","initials":"DF"},{"fullName":"Meisner CR","lastName":"Meisner","firstName":"Carl R","initials":"CR"},{"fullName":"Rosen JB","lastName":"Rosen","firstName":"Jeffrey B","initials":"JB"},{"fullName":"Nunez LD","lastName":"Nunez","firstName":"Lazaro D","initials":"LD"},{"fullName":"Kutner ME","lastName":"Kutner","firstName":"Mark E","initials":"ME"},{"fullName":"Block BM","lastName":"Block","firstName":"Bradley M","initials":"BM"},{"fullName":"Busch RS","lastName":"Busch","firstName":"Robert S","initials":"RS"},{"fullName":"Chow C","lastName":"Chow","firstName":"Christopher","initials":"C"},{"fullName":"Frias JP","lastName":"Frias","firstName":"Juan P","initials":"JP"},{"fullName":"Hsia SH","lastName":"Hsia","firstName":"Stanley H","initials":"SH"},{"fullName":"Kessler E","lastName":"Kessler","firstName":"Evan","initials":"E"},{"fullName":"Layle S","lastName":"Layle","firstName":"Stacey","initials":"S"},{"fullName":"Mehra PK","lastName":"Mehra","firstName":"Purvi K","initials":"PK"},{"fullName":"Mohseni RH","lastName":"Mohseni","firstName":"Rizwana H","initials":"RH"},{"fullName":"Oliver MJ","lastName":"Oliver","firstName":"Michael J","initials":"MJ"},{"fullName":"Rohlf JL","lastName":"Rohlf","firstName":"Jane L","initials":"JL"},{"fullName":"Van JT","lastName":"Van","firstName":"Joanna T","initials":"JT"},{"fullName":"Martin EE","lastName":"Martin","firstName":"Earl E","initials":"EE"},{"fullName":"McCartney MJ","lastName":"McCartney","firstName":"Michael J","initials":"MJ"},{"fullName":"Sorial E","lastName":"Sorial","firstName":"Ehab","initials":"E"},{"fullName":"Soufer J","lastName":"Soufer","firstName":"Joseph","initials":"J"},{"fullName":"Jenders RA","lastName":"Jenders","firstName":"Robert A","initials":"RA"},{"fullName":"Klein EJ","lastName":"Klein","firstName":"Eric J","initials":"EJ"},{"fullName":"Nadar V","lastName":"Nadar","firstName":"Venkatesh","initials":"V"},{"fullName":"Lavery S","lastName":"Lavery","firstName":"Sarah","initials":"S"},{"fullName":"Condren S","lastName":"Condren","firstName":"Stacey","initials":"S"},{"fullName":"Rosenfeld JC","lastName":"Rosenfeld","firstName":"Jack C","initials":"JC"},{"fullName":"Jabbour S","lastName":"Jabbour","firstName":"Serge","initials":"S"},{"fullName":"Vaughn J","lastName":"Vaughn","firstName":"Jordan","initials":"J"},{"fullName":"Gomez-Cuellar M","lastName":"Gomez-Cuellar","firstName":"Martha","initials":"M"},{"fullName":"Sosa-Padilla MA","lastName":"Sosa-Padilla","firstName":"Miguel A","initials":"MA"},{"fullName":"Purighalla RS","lastName":"Purighalla","firstName":"Raman S","initials":"RS"},{"fullName":"Recknor C","lastName":"Recknor","firstName":"Chris","initials":"C"},{"fullName":"Karr AW","lastName":"Karr","firstName":"Aaron W","initials":"AW"},{"fullName":"Mansilla-Letelier P","lastName":"Mansilla-Letelier","firstName":"Paola","initials":"P"},{"fullName":"Cox M","lastName":"Cox","firstName":"Michael","initials":"M"},{"fullName":"Lillestol MJ","lastName":"Lillestol","firstName":"Michael J","initials":"MJ"},{"fullName":"Robinson JG","lastName":"Robinson","firstName":"Jennifer G","initials":"JG"},{"fullName":"True DG","lastName":"True","firstName":"David G","initials":"DG"},{"fullName":"Wynne AG","lastName":"Wynne","firstName":"Alan G","initials":"AG"},{"fullName":"Vazquez-Tanus JB","lastName":"Vazquez-Tanus","firstName":"Jose B","initials":"JB"},{"fullName":"Lucas KJ","lastName":"Lucas","firstName":"Kathryn J","initials":"KJ"},{"fullName":"Murray AV","lastName":"Murray","firstName":"Alexander V","initials":"AV"},{"fullName":"Parker JC","lastName":"Parker","firstName":"John C","initials":"JC"},{"fullName":"Loy J","lastName":"Loy","firstName":"Juan","initials":"J"},{"fullName":"Patel MA","lastName":"Patel","firstName":"Minesh A","initials":"MA"},{"fullName":"Soucie GW","lastName":"Soucie","firstName":"Gary W","initials":"GW"},{"fullName":"Blake D","lastName":"Blake","firstName":"Dwight","initials":"D"},{"fullName":"Huling RT","lastName":"Huling","firstName":"Randall T","initials":"RT"},{"fullName":"Brockmyre AP","lastName":"Brockmyre","firstName":"Andrew P","initials":"AP"},{"fullName":"Blaze K","lastName":"Blaze","firstName":"Kenneth","initials":"K"},{"fullName":"Gabra N","lastName":"Gabra","firstName":"Nashwa","initials":"N"},{"fullName":"Arora S","lastName":"Arora","firstName":"Samir","initials":"S"},{"fullName":"Gupta AK","lastName":"Gupta","firstName":"Anil K","initials":"AK"},{"fullName":"O'Mahony J","lastName":"O'Mahony","firstName":"John","initials":"J"},{"fullName":"Lasko B","lastName":"Lasko","firstName":"Ben","initials":"B"},{"fullName":"Blouin F","lastName":"Blouin","firstName":"Francois","initials":"F"},{"fullName":"Dzongowski P","lastName":"Dzongowski","firstName":"Peter","initials":"P"},{"fullName":"Numair HN","lastName":"Numair","firstName":"Huma N","initials":"HN"},{"fullName":"Patel M","lastName":"Patel","firstName":"Mehulkumar","initials":"M"},{"fullName":"Matin R","lastName":"Matin","firstName":"Roozbeh","initials":"R"},{"fullName":"Ali A","lastName":"Ali","firstName":"Amar","initials":"A"},{"fullName":"Beltran Martinez A","lastName":"Beltran Martinez","firstName":"Adrian","initials":"A"},{"fullName":"Hall T","lastName":"Hall","firstName":"Timothy","initials":"T"},{"fullName":"Toms GR","lastName":"Toms","firstName":"Graham R","initials":"GR"},{"fullName":"Viljoen A","lastName":"Viljoen","firstName":"Adie","initials":"A"},{"fullName":"Johnson T","lastName":"Johnson","firstName":"Timothy","initials":"T"},{"fullName":"Gaunt R","lastName":"Gaunt","firstName":"Richard","initials":"R"},{"fullName":"Gunstone A","lastName":"Gunstone","firstName":"Anthony","initials":"A"},{"fullName":"Marrett PJ","lastName":"Marrett","firstName":"Paula-Jane","initials":"PJ"},{"fullName":"Barnes L","lastName":"Barnes","firstName":"Lawrence","initials":"L"},{"fullName":"Capehorn M","lastName":"Capehorn","firstName":"Matthew","initials":"M"},{"fullName":"Cummings M","lastName":"Cummings","firstName":"Michael","initials":"M"},{"fullName":"Davies M","lastName":"Davies","firstName":"Melanie","initials":"M"},{"fullName":"Randeva HS","lastName":"Randeva","firstName":"Harpal S","initials":"HS"},{"fullName":"Alpizar-Salazar M","lastName":"Alpizar-Salazar","firstName":"Melchor","initials":"M"},{"fullName":"Banda Elizondo RG","lastName":"Banda Elizondo","firstName":"Ramiro G","initials":"RG"},{"fullName":"Calvo Vargas CG","lastName":"Calvo Vargas","firstName":"Cesar G","initials":"CG"},{"fullName":"Nevarez Ruiz LA","lastName":"Nevarez Ruiz","firstName":"Luis A","initials":"LA"},{"fullName":"Violante Ortiz RM","lastName":"Violante Ortiz","firstName":"Rafael M","initials":"RM"},{"fullName":"Garcia Hernandez PA","lastName":"Garcia Hernandez","firstName":"Pedro A","initials":"PA"},{"fullName":"Gonzalez Galvez G","lastName":"Gonzalez Galvez","firstName":"Guillermo","initials":"G"},{"fullName":"Vidrio Velazquez M","lastName":"Vidrio Velazquez","firstName":"Maricela","initials":"M"},{"fullName":"Augusto GA","lastName":"Augusto","firstName":"Gustavo A","initials":"GA"},{"fullName":"Canani LHS","lastName":"Canani","firstName":"Luis Henrique S","initials":"LHS"},{"fullName":"Alves BB","lastName":"Alves","firstName":"Breno B","initials":"BB"},{"fullName":"Franco DR","lastName":"Franco","firstName":"Denise R","initials":"DR"},{"fullName":"Pereira MA","lastName":"Pereira","firstName":"Márcio A","initials":"MA"},{"fullName":"Calil Salim CP","lastName":"Calil Salim","firstName":"Camila P","initials":"CP"},{"fullName":"de Souza FD","lastName":"de Souza","firstName":"Filipe D","initials":"FD"},{"fullName":"Aizenberg D","lastName":"Aizenberg","firstName":"Diego","initials":"D"},{"fullName":"Calella PRF","lastName":"Calella","firstName":"Pedro Rosario Fabian","initials":"PRF"},{"fullName":"Orio SI","lastName":"Orio","firstName":"Silvia I","initials":"SI"},{"fullName":"Fretes JO","lastName":"Fretes","firstName":"José O","initials":"JO"},{"fullName":"Gelersztein E","lastName":"Gelersztein","firstName":"Elizabeth","initials":"E"},{"fullName":"MacKinnon I","lastName":"MacKinnon","firstName":"Ignacio","initials":"I"},{"fullName":"Salzberg S","lastName":"Salzberg","firstName":"Susana","initials":"S"},{"fullName":"Zaidman CJ","lastName":"Zaidman","firstName":"Cesar J","initials":"CJ"},{"fullName":"Coronel MJ","lastName":"Coronel","firstName":"Maria J","initials":"MJ"},{"fullName":"Chertkoff A","lastName":"Chertkoff","firstName":"Alejandro","initials":"A"},{"fullName":"Nardone L","lastName":"Nardone","firstName":"Lucrecia","initials":"L"},{"fullName":"Perez Manghi FC","lastName":"Perez Manghi","firstName":"Federico C","initials":"FC"},{"fullName":"Abalos FH","lastName":"Abalos","firstName":"Franklin H","initials":"FH"},{"fullName":"McCarthy S","lastName":"McCarthy","firstName":"Shannon","initials":"S"},{"fullName":"Kim J","lastName":"Kim","firstName":"Joshua","initials":"J"},{"fullName":"Gilfillan C","lastName":"Gilfillan","firstName":"Christopher","initials":"C","authorId":{"type":"ORCID","value":"0000-0002-8193-8994"}},{"fullName":"Colquhoun DM","lastName":"Colquhoun","firstName":"David M","initials":"DM"},{"fullName":"Purnell PW","lastName":"Purnell","firstName":"Peter W","initials":"PW"},{"fullName":"Bloch MT","lastName":"Bloch","firstName":"Mark T","initials":"MT"},{"fullName":"D'Emden MC","lastName":"D'Emden","firstName":"Michael C","initials":"MC"},{"fullName":"Fiore DD","lastName":"Fiore","firstName":"David Di","initials":"DD"},{"fullName":"Shakib S","lastName":"Shakib","firstName":"Sepehr","initials":"S"},{"fullName":"Zhou ND","lastName":"Zhou","firstName":"Nathan D","initials":"ND"},{"fullName":"Mosenzon Ninio O","lastName":"Mosenzon Ninio","firstName":"Ofri","initials":"O"},{"fullName":"Goldhaber A","lastName":"Goldhaber","firstName":"Adiv","initials":"A"},{"fullName":"Sabbah M","lastName":"Sabbah","firstName":"Muhammad","initials":"M"},{"fullName":"Shehadeh N","lastName":"Shehadeh","firstName":"Naim","initials":"N"},{"fullName":"Tirosh A","lastName":"Tirosh","firstName":"Amir","initials":"A"},{"fullName":"Vishlitzky V","lastName":"Vishlitzky","firstName":"Victor","initials":"V"},{"fullName":"Darawsha M","lastName":"Darawsha","firstName":"Mahmud","initials":"M"},{"fullName":"Sack J","lastName":"Sack","firstName":"Jessica","initials":"J"},{"fullName":"Wainstein J","lastName":"Wainstein","firstName":"Julio","initials":"J"}]},"authorIdList":{"authorId":[{"type":"ORCID","value":"0000-0001-9486-1255"},{"type":"ORCID","value":"0000-0002-8193-8994"},{"type":"ORCID","value":"0000-0002-9987-9371"},{"type":"ORCID","value":"0009-0006-3668-7686"}]},"dataLinksTagsList":{"dataLinkstag":["altmetrics","supporting_data"]},"journalInfo":{"issue":"6","volume":"385","journalIssueId":3213086,"dateOfPublication":"2021 Aug","monthOfPublication":8,"yearOfPublication":2021,"journal":{"medlineAbbreviation":"N Engl J Med","title":"The New England journal of medicine","essn":"1533-4406","issn":"0028-4793","nlmid":"0255562","isoabbreviation":"N Engl J Med"},"printPublicationDate":"2021-08-01"},"pubYear":"2021","pageInfo":"503-515","abstractText":"<h4>Background</h4>Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.<h4>Methods</h4>In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks.<h4>Results</h4>The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide.<h4>Conclusions</h4>In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).","affiliation":"From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre - both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).","publicationStatus":"ppublish","language":"eng","pubModel":"Print-Electronic","pubTypeList":{"pubType":["Clinical Trial, Phase III","Comparative Study","Equivalence Trial","Research Support, Non-U.S. Gov't","Multicenter Study","Randomized Controlled Trial","Journal Article"]},"grantsList":{"grant":[{"agency":"Eli Lilly and Company","orderIn":0}]},"meshHeadingList":{"meshHeading":[{"majorTopic_YN":"N","descriptorName":"Humans"},{"majorTopic_YN":"N","descriptorName":"Diabetes Mellitus, Type 2","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"N","abbreviation":"BL","qualifierName":"blood"},{"majorTopic_YN":"Y","abbreviation":"DT","qualifierName":"drug therapy"}]}},{"majorTopic_YN":"N","descriptorName":"Weight Loss","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"N","abbreviation":"DE","qualifierName":"drug effects"}]}},{"majorTopic_YN":"N","descriptorName":"Nausea","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"N","abbreviation":"CI","qualifierName":"chemically induced"}]}},{"majorTopic_YN":"N","descriptorName":"Metformin","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"N","abbreviation":"TU","qualifierName":"therapeutic use"}]}},{"majorTopic_YN":"N","descriptorName":"Gastric Inhibitory Polypeptide","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"Y","abbreviation":"AD","qualifierName":"administration & dosage"},{"majorTopic_YN":"N","abbreviation":"AE","qualifierName":"adverse effects"}]}},{"majorTopic_YN":"N","descriptorName":"Blood Glucose","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"N","abbreviation":"AN","qualifierName":"analysis"}]}},{"majorTopic_YN":"N","descriptorName":"Hypoglycemic Agents","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"Y","abbreviation":"AD","qualifierName":"administration & dosage"},{"majorTopic_YN":"N","abbreviation":"AE","qualifierName":"adverse effects"},{"majorTopic_YN":"N","abbreviation":"TU","qualifierName":"therapeutic use"}]}},{"majorTopic_YN":"N","descriptorName":"Drug Therapy, Combination"},{"majorTopic_YN":"N","descriptorName":"Injections, Subcutaneous"},{"majorTopic_YN":"N","descriptorName":"Drug Administration Schedule"},{"majorTopic_YN":"N","descriptorName":"Dose-Response Relationship, Drug"},{"majorTopic_YN":"N","descriptorName":"Middle Aged"},{"majorTopic_YN":"N","descriptorName":"Female"},{"majorTopic_YN":"N","descriptorName":"Male"},{"majorTopic_YN":"N","descriptorName":"Glucagon-Like Peptides","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"Y","abbreviation":"AD","qualifierName":"administration & dosage"},{"majorTopic_YN":"N","abbreviation":"AE","qualifierName":"adverse effects"}]}},{"majorTopic_YN":"N","descriptorName":"Incretins","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"N","abbreviation":"TU","qualifierName":"therapeutic use"}]}},{"majorTopic_YN":"N","descriptorName":"Glycated Hemoglobin","meshQualifierList":{"meshQualifier":[{"majorTopic_YN":"N","abbreviation":"AN","qualifierName":"analysis"}]}},{"majorTopic_YN":"N","descriptorName":"Glucagon-Like Peptide-1 Receptor Agonists"},{"majorTopic_YN":"N","descriptorName":"Tirzepatide"},{"majorTopic_YN":"N","descriptorName":"Semaglutide"}]},"chemicalList":{"chemical":[{"name":"Blood Glucose","registryNumber":"0"},{"name":"Hypoglycemic Agents","registryNumber":"0"},{"name":"Gastric Inhibitory Polypeptide","registryNumber":"59392-49-3"},{"name":"Glucagon-Like Peptides","registryNumber":"62340-29-8"},{"name":"Incretins","registryNumber":"0"},{"name":"Metformin","registryNumber":"9100L32L2N"},{"name":"semaglutide","registryNumber":"53AXN4NNHX"},{"name":"tirzepatide","registryNumber":"OYN3CCI6QE"},{"name":"Glycated Hemoglobin","registryNumber":"0"},{"name":"Glucagon-Like Peptide-1 Receptor Agonists","registryNumber":"0"}]},"subsetList":{"subset":[{"code":"IM","name":"Index Medicus"}]},"fullTextUrlList":{"fullTextUrl":[{"availability":"Subscription required","availabilityCode":"S","documentStyle":"doi","site":"DOI","url":"https://doi.org/10.1056/NEJMoa2107519"}]},"commentCorrectionList":{"commentCorrection":[{"source":"MED","id":"34170646","reference":"N Engl J Med. 2021 Aug 5;385(6):560-561. doi: 10.1056/NEJMe2109957.","type":"Comment in","orderIn":1},{"source":"MED","id":"34272516","reference":"Nat Rev Endocrinol. 2021 Sep;17(9):513. doi: 10.1038/s41574-021-00540-y.","type":"Comment in","orderIn":2},{"source":"MED","id":"34724396","reference":"Ann Intern Med. 2021 Nov;174(11):JC127. doi: 10.7326/ACPJ202111160-127.","type":"Comment in","orderIn":3},{"source":"MED","id":"35172065","reference":"N Engl J Med. 2022 Feb 17;386(7):e17. doi: 10.1056/NEJMc2114590.","type":"Comment in","orderIn":4},{"source":"MED","id":"35172066","reference":"N Engl J Med. 2022 Feb 17;386(7):e17. doi: 10.1056/NEJMc2114590.","type":"Comment in","orderIn":5}]},"isOpenAccess":"N","inEPMC":"N","inPMC":"N","citedByCount":1535,"hasReferences":"Y","hasTextMinedTerms":"Y","hasDbCrossReferences":"N","hasPDF":"N","hasBook":"N","hasSuppl":"N","hasLabsLinks":"Y","hasData":"Y","authMan":"N","epmcAuthMan":"N","nihAuthMan":"N","hasTMAccessionNumbers":"Y","tmAccessionTypeList":{"accessionType":["nct"]},"dateOfCompletion":"2021-08-20","dateOfCreation":"2021-06-25","dateOfRevision":"2026-01-27","electronicPublicationDate":"2021-06-25","firstPublicationDate":"2021-06-25","firstIndexDate":"2021-06-26","hasEvaluations":"N"}]}}